BenevolentAI SPAC Presentation Deck

BEN-2293 is expected to provide both symptomatic relief and to reverse disease progression in atopic dermatitis BEN-2293 is highly selective for Trk receptors, with IC50 potencies in the low nM range for TrkA, B, and C ● BEN-2293 dose dependently inhibits release of inflammatory Th1 and Th2 cytokines TNFa, IFNY, IL-13, and IL-4 in human peripheral blood mononuclear cells (PBMCs) stimulated with an inflammatory T-cell stimulus (anti-CD3/CD28) ● BEN-2293 inhibits the release of Calcitonin Gene-Related Peptide (CGRP), a mediator of itch, sensory nerve hypersensitisation and neurogenic inflammation, in dorsal root ganglion (DRG) isolated from adult rats and stimulated with NGF BEN-2293 demonstrates excellent tolerability and safety margins in IND/CTA-enabling toxicology studies Key: Tropomyosin-related kinase (Trk) receptor tyrosine kinase family, namely TrkA, TrkB, and TrkC; Nerve Growth Factor (NGF); Brain Derived Neurotrophic Factor (BDNF); Neurotrophin-3 (NTF-3)/NT3 BEN-2293 Inhibition of human primary T-cell activation Luminescence % inhibition 25000- 20000- 15000- 10000- 5000- 0.1 125- 100- 1 75- 50- 25- 0- -25- -50+ -3 TNFa 10 100 BEN-2293 nM 1000 10000 -2 BEN-2293 mediated inhibition of CGRP in DRG neurons (n=2) Hillslope IC50 - Donor 1 - Donor 2 -1 Log BEN-2293 (μm) 0 2.827 0.03033 Luminescence Human peripheral blood mononuclear cells from 2 blood donors. Stimulated with a T-cell stimulus (anti-CD3/CD28) +/- BEN-2293 1 1500 1000- 500- 0.1 1 IL-4 10 100 1000 10000 BEN-2293 NM -Donor 1 - Donor 2 Inhibition of sensory neuron activation Benevolent 23

View entire presentation